I didnt dial in - seems like things are heading in the right direction and talking up growth and break even this year. Keen to hear if anyone else did.
FY22 Outlook The focus for FY22 will be on accelerating our strong growth by continuing to invest in product development, particularly with respect to new AI tools, and sales initiatives. Growth will be driven by contract wins for AQUILA Enterprise and AQUILA in the Cloud, high recurring revenue, faster conversion of AQUILA in the Cloud, and positive earnings and growth from Radiology Services. We expect this growth in turn to help us reach EBITDA run rate breakeven in FY22.
IME Price at posting:
90.0¢ Sentiment: Buy Disclosure: Held
